Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
NCT06376981

Hyaluronic Acid in Shoulder Tendinopathy

Led by Centre Hospitalier Departemental Vendee · Updated on 2024-10-03

132

Participants Needed

2

Research Sites

130 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Multicentric, randomised study to compare the effectiveness on activity pain at 3 months of corticosteroid injection associated with hyaluronic acid with corticosteroids injection alone in patients with tendinopathy of the supraspinatus with clinical reevaluation at one, three and six months.

CONDITIONS

Official Title

Hyaluronic Acid in Shoulder Tendinopathy

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged between 18 and 65 years
  • Shoulder pain compatible with supraspinatus tendinopathy lasting at least 2 months
  • Simple tendinopathy or partial tendon rupture
  • Tendinopathy confirmed by ultrasound or MRI
  • Active pain with visual analog scale of 4 or higher for more than 6 weeks
  • Active pain with visual analog scale of 4 or higher on the day of inclusion
  • Failure of medical treatment including rest, analgesics, NSAIDs, and physiotherapy
  • Ability to follow study protocol and provide oral informed consent
  • Affiliated with social security or entitled to it
Not Eligible

You will not qualify if you...

  • Transfixing tendon rupture
  • Post-traumatic tendon rupture
  • Calcific tendinopathy with calcification greater than 5 mm
  • Associated glenohumeral osteoarthritis
  • Symptomatic acromioclavicular osteoarthritis
  • Shoulder pain caused by conditions other than tendinopathy such as capsulitis, chronic inflammatory rheumatism, fibromyalgia, or amyloidosis
  • Subacromial infiltration within the previous 6 months
  • Known allergy to study products or their excipients including methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol
  • Known allergy to lidocaine
  • Local or generalized infection or suspected infection
  • Severe coagulation disorders or use of anticoagulants
  • Severe or uncontrolled hypertension above 160/100 mmHg
  • Uncontrolled diabetes with last HbA1c above 8.5%
  • History of addiction to psychoactive substances
  • Participation in another clinical research protocol impacting study objectives
  • Prior randomization in this study
  • Pregnancy, parturition, breastfeeding, or ability to procreate without effective contraception
  • Under guardianship, curatorship, deprived of liberty, or court protection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

CHD Vendée

La Roche-sur-Yon, France

Actively Recruiting

2

CHU Nantes

Nantes, France

Not Yet Recruiting

Loading map...

Research Team

L

Laura SOULARD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here